125372-22-7 Usage
Uses
Used in Pharmaceutical Industry:
Benzoic acid, 2-[(methylamino)sulfonyl]is used as a muscle relaxant for the treatment of acute back pain, musculoskeletal pain, and tension headaches. It is effective in reducing muscle spasms and pain by blocking voltage-gated sodium and calcium channels in the central nervous system.
Used in Pain Management:
Tolperisone is used as a pain management agent, particularly for acute back pain and musculoskeletal pain. Its muscle relaxant properties help to alleviate pain and discomfort associated with muscle spasms and inflammation.
Used in Neurological Disorders:
Benzoic acid, 2-[(methylamino)sulfonyl]is used in the management of certain neurological disorders that involve muscle stiffness and spasms. Its muscle relaxant action helps to improve muscle function and reduce discomfort in patients with these conditions.
Used in Drug Formulations:
Tolperisone is commonly found in pharmaceutical formulations, such as tablets and capsules, for oral administration. It is a popular choice for patients seeking relief from acute back pain, musculoskeletal pain, and tension headaches.
Check Digit Verification of cas no
The CAS Registry Mumber 125372-22-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,3,7 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 125372-22:
(8*1)+(7*2)+(6*5)+(5*3)+(4*7)+(3*2)+(2*2)+(1*2)=107
107 % 10 = 7
So 125372-22-7 is a valid CAS Registry Number.
125372-22-7Relevant academic research and scientific papers
MODIFIED PROTEINS AND PROTEIN DEGRADERS
-
Paragraph 00727; 00730; 00731, (2021/12/08)
Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.
